ELIGIBILITY FOR ANTI-FIBROTIC TREATMENT IN IDIOPATHIC PULMONARY FIBROSIS (IPF) DEPENDS ON THE PREDICTIVE EQUATION USED IN PULMONARY FUNCTION TESTING

被引：0
|
作者：
Burgess, Andrew [1 ]
Goon, Ken [1 ,3 ]
Attia, John [1 ,2 ,3 ]
Palazzi, Kerrin [2 ]
Brannan, John [1 ]
Grainge, Christopher [1 ,2 ,3 ]
机构：
[1] John Hunter Hosp, Newcastle, NSW, Australia
[2] Hunter Med Res Inst, Newcastle, NSW, Australia
[3] Newcastle Univ, Newcastle, NSW, Australia
来源：
RESPIROLOGY | 2017年 / 22卷
关键词：
D O I：
暂无
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
AO103
引用
收藏
页码：46 / 46
页数：1
相关论文
共 50 条
  • [1] Eligibility for anti-fibrotic treatment in idiopathic pulmonary fibrosis depends on the predictive equation used for pulmonary function testing
    Burgess, Andrew
    Goon, Ken
    Brannan, John D.
    Attia, John
    Palazzi, Kerrin
    Oldmeadow, Christopher
    Corte, Tamera J.
    Glaspole, Ian
    Goh, Nicole
    Keir, Gregory
    Allan, Heather
    Chapman, Sally
    Cooper, Wendy
    Ellis, Samantha
    Hopkins, Peter
    Moodley, Yuben
    Reynolds, Paul
    Zappala, Chris
    Macansh, Sacha
    Grainge, Christopher
    [J]. RESPIROLOGY, 2019, 24 (10) : 988 - 995
  • [2] Pirfenidone, a novel anti-fibrotic agent, provides higher benefit for idiopathic pulmonary fibrosis (IPF) patients with better pulmonary function
    Ebina, M.
    Kimura, Y.
    Ohta, H.
    Hisata, S.
    Tamada, T.
    Nukiwa, T.
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2010, 181
  • [3] DISEASE PROGRESSION IN IDIOPATHIC PULMONARY FIBROSIS UNDER ANTI-FIBROTIC TREATMENT
    Cilli, Aykut
    Uzer, Fatih
    [J]. SARCOIDOSIS VASCULITIS AND DIFFUSE LUNG DISEASES, 2023, 40 (03)
  • [4] Characteristics Of Patients With Idiopathic Pulmonary Fibrosis (ipf) Receiving Approved Anti-Fibrotic Therapies In The Us
    Gamerman, V.
    Salisbury, M.
    Culver, D.
    Leonard, T.
    Neely, M. L.
    Yow, E.
    Conoscenti, C. S.
    Palmer, S.
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2017, 195
  • [5] SYSTEMIC ANTI-FIBROTIC EFFECTS OF PIRFENIDONE IN PRECLINICAL STUDIES AND CLINICAL ACTIVITY IN IDIOPATHIC PULMONARY FIBROSIS (IPF)
    Kossen, Karl
    Schaefer, C. J.
    Bradford, W. Z.
    Seiwert, S. D.
    [J]. INFLAMMATION RESEARCH, 2012, 61 : S5 - S5
  • [6] Evaluation of Extracellular Matrix Biomarkers in Response to Anti-Fibrotic Treatment of Idiopathic Pulmonary Fibrosis
    Jessen, H.
    Hoyer, N.
    Ronnow, S.
    Karsdal, M.
    Leeming, D. J.
    Sand, J. M.
    Shaker, S.
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2020, 201
  • [7] A review of Idiopathic Pulmonary Fibrosis patients on anti-fibrotic treatment in the mid west area
    Ryan, N.
    Ryan, P.
    Gleeson, E.
    Cullinan, M.
    Mcinerney, C.
    Casserly, B.
    O'Brien, A.
    [J]. IRISH JOURNAL OF MEDICAL SCIENCE, 2017, 186 (SUPPL 10) : S441 - S442
  • [8] The efficacy of anti-fibrotic agents for acute exacerbation of idiopathic pulmonary fibrosis
    Matsumoto, Yoko
    Furukawa, Ryutaro
    Ohara, Sayaka
    Usui, Kazuhiro
    [J]. EUROPEAN RESPIRATORY JOURNAL, 2017, 50
  • [9] Anti-Fibrotic Therapy and Patient Reported Outcomes in Idiopathic Pulmonary Fibrosis
    Kay, S.
    White, E. S.
    Sheth, J. S.
    Flaherty, C.
    Getty, C.
    Holtze, C.
    Wang, B.
    Salisbury, M.
    Belloli, E.
    Flaherty, K. R.
    Murray, S.
    Xia, M.
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2018, 197
  • [10] Anti-fibrotic role of inhaled interferon-γ in idiopathic pulmonary fibrosis
    Hasaneen, Nadia
    Tuong Vu
    Fusiak, Timothy
    Foda, Hussein
    Condos, Rany
    Smaldone, Gerald
    [J]. EUROPEAN RESPIRATORY JOURNAL, 2015, 46
12345